FDA Adverse Event Malfunction Summary report: N

ARCHITECT HBSAG QUALITATIVE II REAGENT KIT

MDR report key: 17585410 · Received August 21, 2023

Report

Report Number
3008344661-2023-00157
Event Type
Malfunction
Date Received
August 21, 2023
Date of Event
August 1, 2023
Report Date
September 11, 2023
Manufacturer
ABBOTT IRELAND DIAGNOSTICS DIVISION
Product Code
LOM
PMA / PMN Number
P110029
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
IN
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

THE COMPLAINT INVESTIGATION FOR FALSE NONREACTIVE ARCHITECT HBSAG QUALITATIVE II RESULTS INCLUDED A REVIEW OF DATA AND INFORMATION PROVIDED WITHIN THE ARTICLE, SEARCH FOR SIMILAR COMPLAINTS, TICKET TRENDING REVIEW, LABELING REVIEW, AND DEVICE HISTORY RECORD REVIEW. RETURN TESTING WAS NOT COMPLETED AS RETURNS WERE NOT AVAILABLE. TRENDING REVIEW DID NOT IDENTIFY ANY TRENDS FOR THE ISSUE FOR THE PRODUCT. DEVICE HISTORY RECORD REVIEW DID NOT IDENTIFY ANY NON-CONFORMANCES, DEVIATIONS, OR POTENTIAL NON-CONFORMANCES WITH LIST NUMBER 02G22 AND THE COMPLAINT ISSUE. THE OVERALL PERFORMANCE OF THE ARCHITECT HBSAG QUALITATIVE II ASSAY WAS REVIEWED USING FIELD DATA FROM CUSTOMERS WORLDWIDE. THE LOT NUMBER(S) ARE UNKNOWN IN THIS CASE, HOWEVER REVIEW OF THE WITHIN DATE LOTS WITH AT LEAST 2000 PATIENT RESULTS SHOW THAT ALL MEDIAN VALUES ARE WITHIN ±3SD OF THE MEAN INDICATING THAT THE LOTS ARE COMPARABLE AND PERFORMING ACCEPTABLY IN THE FIELD. BASED ON OUR INVESTIGATION, NO SYSTEMIC ISSUE OR DEFICIENCY WITH THE ARCHITECT HBSAG QUALITATIVE II REAGENT WAS IDENTIFIED.

Additional Manufacturer Narrative · 0

AN EVALUATION IS IN PROCESS. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE EVALUATION IS COMPLETE. THIS REPORT IS BEING FILED ON AN INTERNATIONAL PRODUCT, LIST NUMBER 02G22 THAT HAS A SIMILAR PRODUCT DISTRIBUTED IN THE US, LIST NUMBER 4P53.

Description of Event or Problem · 0

A LITERATURE ARTICLE BY ARUL PRAKASH, SURESH PONNUVEL, JOHN DICKSON CALVIN DEVADASAN, KARTHIK NITHYANANDHAN, ABIRAMI BASKARAN, RUNAL JOHN STEVE, T. KALPANA, BAKTHALAL SINGH, ASHISH GOEL, UDAY GEORGE ZACHARIAH, C E EAPEN , RAJESH KANNANGAI, PRIYA ABRAHAM, AND GNANADURAI JOHN FLETCHER, ¿ARCHITECT HBSAG NEXT ASSAY IS POSITIONED BETTER TO RESOLVE AND REFINE CHALLENGING WEAK REACTIVE CLINICAL SAMPLES¿, JOURNAL OF CLINICAL VIROLOGY : THE OFFICIAL PUBLICATION OF THE PAN AMERICAN SOCIETY FOR CLINICAL VIROLOGY 166 : 105524. (JUN 26, 2023), DOCUMENTED A FALSE NONREACTIVE ARCHITECT HBSAG QUALITATIVE II RESULT FOR ONE SAMPLE. THE STUDY NOTED A TOTAL OF 99,761 SERUM SAMPLES WERE RECEIVED FOR ROUTINE ARCHITECT HBSAG QUALITATIVE II TESTING FROM BOTH OUT PATIENTS AND IN-PATIENTS BETWEEN JANUARY 2022 AND 2023. 248 OF THESE SAMPLES WERE INITIAL REACTIVE, AND 68 SAMPLES BECAME NONREACTIVE ON REPEAT TESTING (IN DUPLICATE). ALL SAMPLES WERE THEN TESTED WITH THE ARCHITECT NEXT QUALITATIVE ASSAY. ONE SAMPLE WAS REACTIVE WITH THE ARCHITECT NEXT QUALITATIVE ASSAY BUT WAS NONREACTIVE WITH THE ARCHITECT HBSAG QUALITATIVE II ASSAY AND THE PATIENT WAS CLINICALLY DIAGNOSED WITH CHRONIC HBV INFECTION. NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

Description of Event or Problem · 0

A LITERATURE ARTICLE BY ARUL PRAKASH, SURESH PONNUVEL, JOHN DICKSON CALVIN DEVADASAN, KARTHIK NITHYANANDHAN, ABIRAMI BASKARAN, RUNAL JOHN STEVE, T. KALPANA, BAKTHALAL SINGH, ASHISH GOEL, UDAY GEORGE ZACHARIAH, C E EAPEN , RAJESH KANNANGAI, PRIYA ABRAHAM, AND GNANADURAI JOHN FLETCHER, ¿ARCHITECT HBSAG NEXT ASSAY IS POSITIONED BETTER TO RESOLVE AND REFINE CHALLENGING WEAK REACTIVE CLINICAL SAMPLES¿, JOURNAL OF CLINICAL VIROLOGY : THE OFFICIAL PUBLICATION OF THE PAN AMERICAN SOCIETY FOR CLINICAL VIROLOGY 166 : 105524. (JUN 26, 2023), DOCUMENTED A FALSE NONREACTIVE ARCHITECT HBSAG QUALITATIVE II RESULT FOR ONE SAMPLE. THE STUDY NOTED A TOTAL OF 99,761 SERUM SAMPLES WERE RECEIVED FOR ROUTINE ARCHITECT HBSAG QUALITATIVE II TESTING FROM BOTH OUT PATIENTS AND IN-PATIENTS BETWEEN JANUARY 2022 AND 2023. 248 OF THESE SAMPLES WERE INITIAL REACTIVE, AND 68 SAMPLES BECAME NONREACTIVE ON REPEAT TESTING (IN DUPLICATE). ALL SAMPLES WERE THEN TESTED WITH THE ARCHITECT NEXT QUALITATIVE ASSAY. ONE SAMPLE WAS REACTIVE WITH THE ARCHITECT NEXT QUALITATIVE ASSAY BUT WAS NONREACTIVE WITH THE ARCHITECT HBSAG QUALITATIVE II ASSAY AND THE PATIENT WAS CLINICALLY DIAGNOSED WITH CHRONIC HBV INFECTION. NO IMPACT TO PATIENT MANAGEMENT WAS REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1785806 ARCHITECT HBSAG QUALITATIVE II REAGENT KIT TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM) LOM ABBOTT IRELAND DIAGNOSTICS DIVISION

Patients

Seq Age Sex Outcome Treatment
1 Unknown ARC I2K PROC MOD, 03M74-01, (B)(6) | ARC I2K PROC MOD, 03M74-01, (B)(6)